Evidence map›Paper›PMID 29876778›Full record

ArticleDigestive diseases and sciences2019

Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.

Shirley Cohen-Mekelburg, Stephanie Gold, Yecheskel Schneider, Madison Dennis, Clara Oromendia, Heather Yeo, Fabrizio Michelassi, Ellen Scherl, Adam Steinlauf

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Variation in Provider Connectedness Associates With Outcomes of Inflammatory Bowel Diseases in an Analysis of Data From a National Health System.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021
    Article
  6. Observational
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shirley Cohen-MekelburgDivision of Gastroenterology and Hepatology, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA. shc9085@nyp.org.ORCID 0000-0001-5058-5527
Stephanie GoldDepartment of Medicine, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Yecheskel SchneiderDivision of Gastroenterology and Hepatology, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Madison DennisDepartment of Medicine, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Clara OromendiaDivision of Healthcare Policy and Research, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Heather YeoDepartment of Surgery, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Fabrizio MichelassiDepartment of Surgery, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Ellen ScherlDivision of Gastroenterology and Hepatology, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Adam SteinlaufDivision of Gastroenterology and Hepatology, New York Presbyterian Weill Cornell Medical Center, New York, NY, 10021, USA.
Cornell University · USNewYork–Presbyterian Hospital · US

Funding

Clinical and Translational Science Center at Weill Cornell Medical UL1-TR000457-06National Center for Advancing Translational Science of the National Institute of Health UL1TR000457
6 · The paper itself

Abstract

backgroundStudies have shown that prophylactic biologic therapy can reduce post-surgical Crohn's disease recurrence.

aimsWe aimed to identify the frequency of delay and risk factors associated with a delay in the initiation of prophylactic post-surgical biologic therapy in high-risk patients.

methodsWe performed a cohort study of Crohn's disease patients who underwent a bowel resection. We identified those at risk of recurrence and explored multiple characteristics for those with and without a delay post-operatively.

resultsA total of 84 patients were included in our analysis of which 69.0% had a greater than 4-week delay and 56.0% a greater than 8-week delay in post-surgical biologic prophylaxis. Publicly insured patients had a 100% delay in post-surgical prophylaxis initiation (p = 0.039, p = 0.003 at 4 and 8 weeks, respectively). Patients on a biologic pre-surgery were less likely to have a delay (p < 0.001) in post-operative prophylaxis. Care at an inflammatory bowel disease (IBD) center was associated with timely therapy when considering a post-operative immunomodulator or biologic strategy.

conclusionsThere are a substantial number of delays in initiating post-operative prophylactic biologic therapy in high-risk patients. Identifying susceptible patients by insurance type or absence of pre-operative therapy can focus future improvement efforts. Additionally, consultation with IBD-specialized providers should be considered in peri-surgical IBD care.

Indexed as

Digestive System Surgical ProceduresAdalimumabAdultAntibodies, Monoclonal, HumanizedBiological ProductsCecumCertolizumab PegolCohort StudiesColectomyCrohn DiseaseFemaleHumansIleumInfliximabInsurance, HealthIntestine, SmallAdalimumabAntibodies, Monoclonal, HumanizedBiological ProductsCertolizumab PegolInfliximabvedolizumabInflammatory bowel diseasePreventive carePublic payerSurgery

Identifiers

PMID29876778
OpenAlexW2807242562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.